Document is current
Any future updates will be listed below
-
Authors
Krastev, Dragomir B. https://orcid.org/0000-0003-4298-7272
Li, Shudong
Sun, Yilun https://orcid.org/0000-0002-6249-2704
Wicks, Andrew J. https://orcid.org/0000-0002-9307-3262
Hoslett, Gwendoline https://orcid.org/0000-0002-0030-7761
Weekes, Daniel
Badder, Luned M.
Knight, Eleanor G.
Marlow, Rebecca
Pardo, Mercedes Calvo https://orcid.org/0000-0002-3477-9695
Yu, Lu https://orcid.org/0000-0001-8378-9112
Talele, Tanaji T.
Bartek, Jiri https://orcid.org/0000-0003-2013-7525
Choudhary, Jyoti S. https://orcid.org/0000-0003-0881-5477
Pommier, Yves
Pettitt, Stephen J. https://orcid.org/0000-0003-3313-3857
Tutt, Andrew N. J. https://orcid.org/0000-0001-8715-2901
Ramadan, Kristijan https://orcid.org/0000-0001-5522-021X
Lord, Christopher J. https://orcid.org/0000-0002-3226-0515
- License Information
-
More Information
Article History
Received: 19 February 2021
Accepted: 3 November 2021
First Online: 10 January 2022
Competing interests
: T.T.T. is a co-founder of Hysplex, LLC, with interests in PARPi development. C.J.L. makes the following disclosures: is/has been a consultant for AstraZeneca, Merck KGaA, Artios, Syncona, Sun Pharma, Gerson Lehrman Group, Vertex, Tango, 3rd Rock, Ono Pharma, Dark Blue Therapeutics, Horizon Discovery and Abingworth; has received grant/research support from AstraZeneca, Artios and Merck KGaA; is a stockholder in Tango and Ovibio; and stands to gain from the use of PARP and other DNA-repair inhibitors as part of the Institute of Cancer Research ‘rewards to inventors’ scheme. A.N.J.T. is/has been a consultant for AstraZeneca, Merck KGaA, Artios, Pfizer, Vertex, GE Healthcare, Inbiomotion and MD Anderson Cancer Centre; has received grant/research support from AstraZeneca, Myriad, Medivation and Merck KGaA; is a stockholder in Inbiomotion; and stands to gain from the use of PARPi as part of the Institute of Cancer Research ‘rewards to inventors’ scheme. The remaining authors declare no competing interests.
